Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): results from DESTINY-Breast06